Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: an international YO-IFOS survey.

[en] [en] PURPOSE: To investigate the consistency between the international guidelines recommendations and worldwide standard practices regarding diagnostic work-up and follow-up strategies for managing patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in the era of monoclonal antibodies. METHODS: A questionnaire developed by the Rhinology section of the Young Otolaryngologists of the International Federation of Oto-rhino-laryngological Societies (Yo-IFOS) included items regarding the management of CRSwNP patients, monoclonal prescription, surgical and follow-up procedures, awareness of biologicals availability, and other relevant clinical practices. The online survey was directed to otolaryngologists and distributed in Europe, North America, South America, and the Middle East through otolaryngological and/or rhinological societies. RESULTS: A total of 202 responses were analyzed; the mean participants' age was 45 ± 11 (73% men and 27% women), and 31% were from the United States, Canada 19%, Europe 45%, Middle East and South America 5%. Only 60% of the respondents declared using validated symptoms and endoscopic score systems in their clinical practice. Several practice discrepancies emerged in our cohort, including preferred surgical approach, prescription of preoperative oral steroids, and perioperative antibiotics (59% and 58%, respectively), as well as divergent awareness levels of available biologics for CRSwNP worldwide. CONCLUSIONS: CRSwNP needs a complex and time-consuming assessment, according to the latest guidelines. There seems to be a gap between these recommendations and the real-world data, which should draw more attention to bringing them into uniform clinical practice in the near future.

Disciplines :

Otolaryngology

Author, co-author :

Maza-Solano, Juan ; Rhinology Unit, Department of Otolaryngology-Head and Neck Surgery, University Hospital Virgen Macarena, Seville, Spain

Biadsee, Ameen ; Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada. Ameenbiadsee@gmail.com ; Department of Otolaryngology-Head and Neck Surgery, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Ameenbiadsee@gmail.com

Sowerby, Leigh J ; Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada

Calvo-Hernández, Christian ; Department of Otolaryngology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain

Tucciarone, Manuel ; Department of Otolaryngology and Head and Neck Surgery, University Hospital of Jerez, Cádiz, Spain

Rocha, Taciano ; Department of Otolaryngology-Head and Neck Surgery, Western University, London, ON, Canada

Maniaci, Antonino ; Department of Medical, Surgical Sciences and Advanced Technologies G.F. Ingrassia, University of Catania, Catania, Italy

Saibene, Alberto Maria ; Otolaryngology Unit, Santi Paolo e Carlo Hospital, Department of Health Sciences, Università Degli Studi di Milano, Milan, Italy

Chiesa-Estomba, Carlos M ; Otorhinolaryngology-Head and Neck Surgery Department, Donostia University Hospital, Biodonostia Research Institute, St. Sebastien, Spain

Radulesco, Thomas ; Department of Oto-Rhino-Laryngology Head and Neck Surgery, Aix-Marseille Univ, APHM, IUSTI, CNRS, La Conception University Hospital, Marseille, France

More authors (4 more)

Language :

English

Title :

Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: an international YO-IFOS survey.

Publication date :

01 December 2022

Journal title :

European Archives of Oto-Rhino-Laryngology

ISSN :

0937-4477

eISSN :

1434-4726

Publisher :

Springer Science and Business Media Deutschland GmbH, Germany

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://link.springer.com/content/pdf/10.1007/s00405-022-07762-4.pdf

Research unit :

P362 - Métrologie et Sciences du langage

Research institute :

R550 - Institut des Sciences et Technologies de la Santé
R350 - Institut de recherche en sciences et technologies du langage

Available on ORBi UMONS :

since 09 February 2023

Statistics

Number of views

16 (1 by UMONS)

Number of downloads

66 (0 by UMONS)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Roland LT, Smith TL, Schlosser RJ et al (2020) Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop. Int Forum Allergy Rhinol 10(9):1037–1042. 10.1002/alr.22633 DOI: 10.1002/alr.22633
Orlandi RR, Kingdom TT, Smith TL et al (2021) International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol 11(3):213–739. 10.1002/alr.22741 DOI: 10.1002/alr.22741
Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(S29):1–464. 10.4193/Rhin20.600 DOI: 10.4193/Rhin20.600
Fokkens WJ, Lund V, Bachert C et al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74(12):2312–2319. 10.1111/all.13875 DOI: 10.1111/all.13875
Thamboo A, Kilty S, Witterick I et al (2021) Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. J Otolaryngol Head Neck Surg 50(1):15. 10.1186/s40463-021-00493-2 DOI: 10.1186/s40463-021-00493-2
Bachert C, Han JK, Desrosiers M et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638–1650. 10.1016/S0140-6736(19)31881-1 DOI: 10.1016/S0140-6736(19)31881-1
Gevaert P, Omachi TA, Corren J et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146(3):595–605. 10.1016/j.jaci.2020.05.032 DOI: 10.1016/j.jaci.2020.05.032
Han JK, Bachert C, Fokkens W et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141–1153. 10.1016/S2213-2600(21)00097-7 DOI: 10.1016/S2213-2600(21)00097-7
Bachert C, Han JK, Desrosiers MY et al (2022) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol 149(4):1309-1317.e12. 10.1016/j.jaci.2021.08.030 DOI: 10.1016/j.jaci.2021.08.030
Biadsee A, Payne S, Sowerby LJ (2022) Can we make biologic therapy more affordable? Int Forum Allergy Rhinol. 10.1002/alr.23039 DOI: 10.1002/alr.23039
Swisher AR, Kshirsagar RS, Adappa ND, Liang J (2021) Dupilumab adverse events in nasal polyp treatment: analysis of FDA adverse event reporting system. Laryngoscope. 10.1002/lary.29992 DOI: 10.1002/lary.29992
Sharma A, Minh Duc NT, Luu Lam Thang T et al (2021) A consensus-based checklist for reporting of survey studies (CROSS). J Gen Intern Med 36(10):3179–3187. 10.1007/s11606-021-06737-1 DOI: 10.1007/s11606-021-06737-1
Liu M, Liu J, Weitzel EK, Chen PG (2022) The predictive utility of the 22-item sino-nasal outcome test (SNOT-22): a scoping review. Int Forum Allergy Rhinol 12(1):83–102. 10.1002/alr.22888 DOI: 10.1002/alr.22888
Meltzer EO, Hamilos DL, Hadley JA et al (2004) Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 114(6 Suppl):155–212. 10.1016/j.jaci.2004.09.029 DOI: 10.1016/j.jaci.2004.09.029
Psaltis AJ, Li G, Vaezeafshar R, Cho KS, Hwang PH (2014) Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope 124(10):2216–2223. 10.1002/lary.24654 DOI: 10.1002/lary.24654
O’Brien WT Sr, Hamelin S, Weitzel EK (2016) The preoperative sinus CT: avoiding a “CLOSE” call with surgical complications. Radiology 281(1):10–21. 10.1148/radiol.2016152230 DOI: 10.1148/radiol.2016152230
Maza-Solano JM, González-García J, Moreno-Luna R, Ambrosiani-Fernández J, Domínguez-Durán E, Sánchez-Gómez S (2018) “ABCDEF Checklist” based on 3D radiological images for preoperative planning of endoscopic sinus surgery. Rhinology Online 1:133–142. 10.4193/RHINOL/18.054 DOI: 10.4193/RHINOL/18.054
Sedaghat AR, Kuan EC, Scadding GK (2022) Epidemiology of chronic rhinosinusitis: prevalence and risk factors. J Allergy Clin Immunol Pract 10(6):1395–1403. 10.1016/j.jaip.2022.01.016 DOI: 10.1016/j.jaip.2022.01.016
Stevens WW, Peters AT, Tan BK et al (2019) Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract 7(8):2812-2820.e3. 10.1016/j.jaip.2019.05.009 DOI: 10.1016/j.jaip.2019.05.009
Matucci A, Nencini F, Maggiore G et al (2022) High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients. Clin Exp Allergy. 10.1111/cea.14153 DOI: 10.1111/cea.14153
Fokkens WJ, Lund V, Luong AU, Orlandi RR (2022) A comparison of international guidelines for rhinosinusitis. J Allergy Clin Immunol Pract 10(6):1418–1422. 10.1016/j.jaip.2022.01.013 DOI: 10.1016/j.jaip.2022.01.013
Meirte J, Hellemans N, Anthonissen M et al (2020) Benefits and disadvantages of electronic patient-reported outcome measures: systematic review. JMIR Perioper Med 3(1):e15588. 10.2196/15588 DOI: 10.2196/15588
Robinson D, Humbert M, Buhl R et al (2017) Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 47(2):161–175. 10.1111/cea.12880 DOI: 10.1111/cea.12880
Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract 9(3):1133–1141. 10.1016/j.jaip.2020.09.063 DOI: 10.1016/j.jaip.2020.09.063
De Corso E, Lucidi D, Battista M et al (2017) Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? Int Forum Allergy Rhinol 7(9):861–867. 10.1002/alr.21979 DOI: 10.1002/alr.21979
Rimmer J, Hellings P, Lund VJ et al (2019) European position paper on diagnostic tools in rhinology. Rhinology 57(S28):1–41. 10.4193/Rhin19.410 DOI: 10.4193/Rhin19.410
Coates ML, Martinez Del Pero M (2020) Updates in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for the ENT surgeon. Clin Otolaryngol 45(3):316–326. 10.1111/coa.13524 DOI: 10.1111/coa.13524
Yamazaki K, Nomizo T, Hatanaka K et al (2022) Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab. J Allergy Clin Immunol 1(3):180–182. 10.1016/j.jacig.2022.03.006 DOI: 10.1016/j.jacig.2022.03.006
Patel GB, Peters AT (2021) The role of biologics in chronic rhinosinusitis with nasal polyps. Ear Nose Throat J 100(1):44–47. 10.1177/0145561320964653 DOI: 10.1177/0145561320964653
Hopkins C, Browne JP, Slack R et al (2006) The national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Clin Otolaryngol 31(5):390–398. 10.1111/j.1749-4486.2006.01275.x DOI: 10.1111/j.1749-4486.2006.01275.x
Le PT, Soler ZM, Jones R, Mattos JL, Nguyen SA, Schlosser RJ (2018) Systematic review and meta-analysis of SNOT-22 outcomes after surgery for chronic rhinosinusitis with nasal polyposis. Otolaryngol Head Neck Surg 159(3):414–423. 10.1177/0194599818773065 DOI: 10.1177/0194599818773065
Wu Q, Zhang Y, Kong W et al (2022) Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol 183(3):279–288. 10.1159/000519228 DOI: 10.1159/000519228
Longino ES, Labby AB, Wu J et al (2022) Association of cytokine profile with prior treatment failure and revision surgery in chronic rhinosinusitis. Int Forum Allergy Rhinol. 10.1002/alr.23035 DOI: 10.1002/alr.23035
Chapurin N, Li P, Chandra RK, Turner JH, Chowdhury NI (2021) Elevated mucus interleukin-17A levels are associated with increased prior sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol 11(2):120–127. 10.1002/alr.22652 DOI: 10.1002/alr.22652
Kim J, Naclerio R (2020) Therapeutic potential of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps: evidence to date. Ther Clin Risk Manag 16:31–37. 10.2147/TCRM.S210648 DOI: 10.2147/TCRM.S210648
Dharmarajan H, Falade O, Lee SE, Wang EW (2021) Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 10.1002/alr.22951 DOI: 10.1002/alr.22951
Scangas GA, Wu AW, Ting JY et al (2021) Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope 131(1):E26–E33. 10.1002/lary.28648 DOI: 10.1002/lary.28648
Cabana MD, Rand CS, Powe NR et al (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458–1465. 10.1001/jama.282.15.1458 DOI: 10.1001/jama.282.15.1458
Rosenfeld RM, Andes D, Bhattacharyya N et al (2007) Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 137(3 Suppl):S1–S31. 10.1016/j.otohns.2007.06.726 DOI: 10.1016/j.otohns.2007.06.726
Alweis R, Greco M, Wasser T, Wenderoth S (2014) An initiative to improve adherence to evidence-based guidelines in the treatment of URIs, sinusitis, and pharyngitis. J Community Hosp Intern Med Perspect 4(1):22958. 10.3402/jchimp.v4.22958 DOI: 10.3402/jchimp.v4.22958
Korkeila K, Suominen S, Ahvenainen J et al (2001) Non-response and related factors in a nation-wide health survey. Eur J Epidemiol 17(11):991–999. 10.1023/A:1020016922473 DOI: 10.1023/A:1020016922473